Loading...

Ezra Cohen

Title(s)Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC
    NIH/NCI R01CA247551Dec 1, 2019 - Nov 30, 2024
    Role: Co-Principal Investigator
    Therapeutic Targeting of Macrophage PI3Kgamma in HNSCC
    NIH/NCI R01CA226909Apr 17, 2018 - Mar 31, 2023
    Role: Co-Principal Investigator
    A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States
    NIH/NCI U01CA217885Sep 12, 2017 - Jul 31, 2022
    Role: Co-Principal Investigator
    Maximizing Efficacy of EGFR Inhibitors by Defining Resistance Mechanisms
    NIH/NIDCR R21DE022454Aug 15, 2012 - Jul 31, 2014
    Role: Principal Investigator
    Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
    NIH/NCI R01CA134633May 10, 2009 - May 31, 2022
    Role: Co-Principal Investigator
    Functional Infrared Imaging Predicts Radiation Mucositis
    NIH/NCI R21CA125000Sep 1, 2007 - Aug 31, 2010
    Role: Principal Investigator
    Rapamycin as an Antineoplastic Agent
    NIH/NCI R21CA112951Jun 6, 2005 - May 31, 2008
    Role: Principal Investigator
    Basic Medical Research Training in Oncology
    NIH/NCI T32CA009566Sep 5, 1987 - Sep 29, 1997
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clin Cancer Res. 2020 Jul 15. Harrington KJ, Kong A, Mach N, Chesney JA, Fernandez BC, Rischin D, Cohen EEW, Radcliffe HS, Gumuscu B, Cheng J, Snyder W, Siu LL. PMID: 32669371.
      View in: PubMed   Mentions:    Fields:    
    2. Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study. J Clin Oncol. 2020 Jul 20; 38(21):2427-2437. Powell SF, Gold KA, Gitau MM, Sumey CJ, Lohr MM, McGraw SC, Nowak RK, Jensen AW, Blanchard MJ, Fischer CD, Bykowski J, Ellison CA, Black LJ, Thompson PA, Callejas-Valera JL, Lee JH, Cohen EEW, Spanos WC. PMID: 32479189.
      View in: PubMed   Mentions:    Fields:    
    3. Quality of Life With Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. J Natl Cancer Inst. 2020 05 14. Harrington KJ, Soulières D, Le Tourneau C, Dinis J, Licitra LF, Ahn MJ, Soria A, Machiels JH, Mach N, Mehra R, Burtness B, Ellison MC, Cheng JD, Chirovsky DR, Swaby RF, Cohen EEW. PMID: 32407532.
      View in: PubMed   Mentions:    Fields:    
    4. Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors. Biomaterials. 2020 Jul; 248:120032. Hingorani DV, Crisp JL, Doan MK, Camargo MF, Quraishi MA, Aguilera J, Gilardi M, Gross LA, Jiang T, Li WT, Ongkeko WM, Cohen EEW, Gutkind JS, Adams SR, Advani SJ. PMID: 32304937.
      View in: PubMed   Mentions:    Fields:    
    5. B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. Clin Cancer Res. 2020 Jul 01; 26(13):3345-3359. Kim SS, Shen S, Miyauchi S, Sanders PD, Franiak-Pietryga I, Mell L, Gutkind JS, Cohen EEW, Califano JA, Sharabi AB. PMID: 32193227.
      View in: PubMed   Mentions: 2     Fields:    
    6. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. J Med Econ. 2020 May; 23(5):442-447. Haddad R, Cohen EEW, Venkatachalam M, Young K, Singh P, Shaw JW, Korytowsky B, Abraham P, Harrington KJ. PMID: 31928375.
      View in: PubMed   Mentions: 1     Fields:    
    7. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Transl Med. 2019 12 26; 17(1):429. Pai SI, Cohen EEW, Lin D, Fountzilas G, Kim ES, Mehlhorn H, Baste N, Clayburgh D, Lipworth L, Resteghini C, Shara N, Fujii T, Zhang J, Stokes M, Wang H, Twumasi-Ankrah P, Wildsmith S, Khaliq A, Melillo G, Shire N. PMID: 31878938.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer. Cancer Res. 2020 02 15; 80(4):732-746. Miyauchi S, Sanders PD, Guram K, Kim SS, Paolini F, Venuti A, Cohen EEW, Gutkind JS, Califano JA, Sharabi AB. PMID: 31848196.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    9. Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. Nat Commun. 2019 12 05; 10(1):5546. Wang Z, Wu VH, Allevato MM, Gilardi M, He Y, Luis Callejas-Valera J, Vitale-Cross L, Martin D, Amornphimoltham P, Mcdermott J, Yung BS, Goto Y, Molinolo AA, Sharabi AB, Cohen EEW, Chen Q, Lyons JG, Alexandrov LB, Gutkind JS. PMID: 31804466.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    10. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. J Immunother Cancer. 2019 12 04; 7(1):342. Cohen EEW, Pishvaian MJ, Shepard DR, Wang D, Weiss J, Johnson ML, Chung CH, Chen Y, Huang B, Davis CB, Toffalorio F, Thall A, Powell SF. PMID: 31801624.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    11. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial. Ann Oncol. 2019 11 01; 30(11):1831-1839. Guo Y, Ahn MJ, Chan A, Wang CH, Kang JH, Kim SB, Bello M, Arora RS, Zhang Q, He X, Li P, Dechaphunkul A, Kumar V, Kamble K, Li W, Kandil A, Cohen EEW, Geng Y, Zografos E, Tang PZ. PMID: 31501887.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    12. p16 status and choice of chemotherapy in the KEYNOTE-040 study - Authors' reply. Lancet. 2019 10 12; 394(10206):1323. Cohen EEW, Soulières D, Swaby RF, Harrington KJ. PMID: 31609223.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability. Mol Cancer Ther. 2020 01; 19(1):157-167. Hingorani DV, Doan MK, Camargo MF, Aguilera J, Song SM, Pizzo D, Scanderbeg DJ, Cohen EEW, Lowy AM, Adams SR, Advani SJ. PMID: 31597712.
      View in: PubMed   Mentions:
    14. Selection of Head and Neck Cancer Patients for Intensive Therapy. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):157-166. Vitzthum LK, Park H, Zakeri K, Bryant AK, Feng C, Shen H, Cohen EEW, Murphy JD, Mell LK. PMID: 31580929.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. Oral Oncol. 2019 10; 97:82-91. Haddad R, Guigay J, Keilholz U, Clement PM, Fayette J, de Souza Viana L, Rolland F, Cupissol D, Geoffrois L, Kornek G, Licitra L, Melichar B, Ribaldo Nicolau U, Rauch D, Zanetta-Devauges S, Cohen EEW, Machiels JP, Tahara M, Vermorken J, Geng Y, Zografos E, Gauler T. PMID: 31450171.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    16. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019 07 15; 7(1):184. Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. PMID: 31307547.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    17. Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial. JAMA Oncol. 2019 Jun 13. Burtness B, Haddad R, Dinis J, Trigo J, Yokota T, de Souza Viana L, Romanov I, Vermorken J, Bourhis J, Tahara M, Martins Segalla JG, Psyrri A, Vasilevskaya I, Nangia CS, Chaves-Conde M, Kiyota N, Homma A, Holeckova P, Del Campo JM, Asarawala N, Nicolau UR, Rauch D, Even C, Wang B, Gibson N, Ehrnrooth E, Harrington K, Cohen EEW. PMID: 31194247.
      View in: PubMed   Mentions: 1     Fields:    
    18. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. Front Immunol. 2019; 10:491. Guram K, Kim SS, Wu V, Sanders PD, Patel S, Schoenberger SP, Cohen EEW, Chen SY, Sharabi AB. PMID: 30936880.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    19. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. Clin Cancer Res. 2019 07 15; 25(14):4211-4223. Miyauchi S, Kim SS, Pang J, Gold KA, Gutkind JS, Califano JA, Mell LK, Cohen EEW, Sharabi AB. PMID: 30814108.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    20. Prognostic Role of p16 in Nonoropharyngeal Head and Neck Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1393-1399. Bryant AK, Sojourner EJ, Vitzthum LK, Zakeri K, Shen H, Nguyen C, Murphy JD, Califano JA, Cohen EEW, Mell LK. PMID: 29878161.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    21. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019 01 12; 393(10167):156-167. Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ. PMID: 30509740.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansCTClinical Trials
    22. Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens. Cancer Immunol Res. 2019 01; 7(1):40-49. Miller AM, Bahmanof M, Zehn D, Cohen EEW, Schoenberger SP. PMID: 30482746.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    23. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. JAMA Oncol. 2018 11 01; 4(11):1583-1588. Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW. PMID: 29931076.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    24. Characterizing an Ultra-High-Risk Subset of Patients With Hypopharynx and Larynx Cancer: The Power of Lymph Node Burden. JAMA Oncol. 2018 07 01; 4(7):989-990. Orosco RK, Cohen EE. PMID: 29192300.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317. Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR. PMID: 29948021.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    26. Interdisciplinary Oncology Education: a National Survey of Trainees and Program Directors in the United States. J Cancer Educ. 2018 06; 33(3):622-626. Akthar AS, Hellekson CD, Ganai S, Hahn OM, Maggiore RJ, Cohen EE, Posner MC, Chmura SJ, Howard AR, Golden DW. PMID: 27873183.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2018 07; 82:83-90. Ferrarotto R, William WN, Tseng JE, Marur S, Shin DM, Murphy B, Cohen EEW, Thomas CY, Willey R, Cosaert J, Harun N, Jack Lee J, Wistuba IW, Haddad RI, Glisson BS. PMID: 29909907.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    28. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Ann Oncol. 2018 05 01; 29(5):1130-1140. Haddad RI, Posner M, Hitt R, Cohen EEW, Schulten J, Lefebvre JL, Vermorken JB. PMID: 29635316.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    29. Positive Surgical Margins in the 10 Most Common Solid Cancers. Sci Rep. 2018 04 09; 8(1):5686. Orosco RK, Tapia VJ, Califano JA, Clary B, Cohen EEW, Kane C, Lippman SM, Messer K, Molinolo A, Murphy JD, Pang J, Sacco A, Tringale KR, Wallace A, Nguyen QT. PMID: 29632347.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    30. Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. Oral Oncol. 2018 05; 80:16-22. Foster CC, Melotek JM, Brisson RJ, Seiwert TY, Cohen EEW, Stenson KM, Blair EA, Portugal L, Gooi Z, Agrawal N, Vokes EE, Haraf DJ. PMID: 29706184.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    31. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol. 2017 Nov 01; 28(11):2813-2819. Schlumberger M, Elisei R, Müller S, Schöffski P, Brose M, Shah M, Licitra L, Krajewska J, Kreissl MC, Niederle B, Cohen EEW, Wirth L, Ali H, Clary DO, Yaron Y, Mangeshkar M, Ball D, Nelkin B, Sherman S. PMID: 29045520.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    32. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Ann Oncol. 2017 Oct 01; 28(10):2526-2532. Cohen EEW, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, Del Campo JM, Mailliez A, Haddad RI, Vermorken JB, Tahara M, Guigay J, Geoffrois L, Merlano MC, Dupuis N, Krämer N, Cong XJ, Gibson N, Solca F, Ehrnrooth E, Machiels JH. PMID: 28961833.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    33. Serum antibodies open the door to prediction and prognostication in human papillomavirus-related head and neck cancer. Cancer. 2017 11 15; 123(22):4310-4313. Sacco AG, Cohen EE. PMID: 28950413.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    34. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2017 09 21; 2(18). Sato-Kaneko F, Yao S, Ahmadi A, Zhang SS, Hosoya T, Kaneda MM, Varner JA, Pu M, Messer KS, Guiducci C, Coffman RL, Kitaura K, Matsutani T, Suzuki R, Carson DA, Hayashi T, Cohen EE. PMID: 28931759.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    35. Does chemoselection open the door for immunotherapy? Ann Oncol. 2017 08 01; 28(8):1697-1699. Jacobs MT, Ruiz AL, Cohen EE. PMID: 28541375.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. Rising incidence of oral tongue cancer among white men and women in the United States, 1973-2012. Oral Oncol. 2017 04; 67:146-152. Tota JE, Anderson WF, Coffey C, Califano J, Cozen W, Ferris RL, St John M, Cohen EE, Chaturvedi AK. PMID: 28351569.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    37. Corrigendum: PI3K? is a molecular switch that controls immune suppression. Nature. 2017 02 02; 542(7639):124. Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, Woo G, Nguyen AV, Figueiredo CC, Foubert P, Schmid MC, Pink M, Winkler DG, Rausch M, Palombella VJ, Kutok J, McGovern K, Frazer KA, Wu X, Karin M, Sasik R, Cohen EE, Varner JA. PMID: 27974794.
      View in: PubMed   Mentions: 5     Fields:    
    38. Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. Nat Commun. 2016 10 04; 7:13019. Adams SR, Yang HC, Savariar EN, Aguilera J, Crisp JL, Jones KA, Whitney MA, Lippman SM, Cohen EE, Tsien RY, Advani SJ. PMID: 27698471.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    39. PI3K? is a molecular switch that controls immune suppression. Nature. 2016 11 17; 539(7629):437-442. Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, Woo G, Nguyen AV, Figueiredo CC, Foubert P, Schmid MC, Pink M, Winkler DG, Rausch M, Palombella VJ, Kutok J, McGovern K, Frazer KA, Wu X, Karin M, Sasik R, Cohen EE, Varner JA. PMID: 27642729.
      View in: PubMed   Mentions: 171     Fields:    Translation:HumansAnimalsCells
    40. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 2016 Dec 15; 122(24):3856-3864. Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen EE, Schöffski P, Wirth LJ, Mangeshkar M, Aftab DT, Brose MS. PMID: 27525386.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    41. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1272-82. Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. PMID: 27460442.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    42. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9. Seiwert TY, Melotek JM, Blair EA, Stenson KM, Salama JK, Witt ME, Brisson RJ, Chawla A, Dekker A, Lingen MW, Kocherginsky M, Villaflor VM, Cohen EE, Haraf DJ, Vokes EE. PMID: 27511844.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    43. Considering the survivorship care needs of head and neck cancer survivors. Oral Oncol. 2016 06; 57:61-2. Abbott DM, Cohen EE, Sadeghi N, Stein KD, Erb NL. PMID: 27130576.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    44. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Ann Oncol. 2016 08; 27(8):1585-93. Clement PM, Gauler T, Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Cohen EE, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Vermorken JB. PMID: 27084954.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    45. A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis. PLoS One. 2016; 11(4):e0152995. Chen P, Mancini M, Sonis ST, Fernandez-Martinez J, Liu J, Cohen EE, Toback FG. PMID: 27049860.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    46. American Cancer Society Head and Neck Cancer Survivorship Care Guideline. CA Cancer J Clin. 2016 05; 66(3):203-39. Cohen EE, LaMonte SJ, Erb NL, Beckman KL, Sadeghi N, Hutcheson KA, Stubblefield MD, Abbott DM, Fisher PS, Stein KD, Lyman GH, Pratt-Chapman ML. PMID: 27002678.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    47. A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. Oncotarget. 2016 Mar 08; 7(10):10696-709. Yamaguchi K, Iglesias-Bartolomé R, Wang Z, Callejas-Valera JL, Amornphimoltham P, Molinolo AA, Cohen EE, Califano JA, Lippman SM, Luo J, Gutkind JS. PMID: 26882569.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    48. Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13. Villaflor VM, Melotek JM, Karrison TG, Brisson RJ, Blair EA, Portugal L, De Souza JA, Ginat DT, Stenson KM, Langerman A, Kocherginsky M, Spiotto MT, Hannigan N, Seiwert TY, Cohen EE, Vokes EE, Haraf DJ. PMID: 26884588.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    49. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol. 2016 Feb; 2(2):209-16. William WN, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM. PMID: 26540028.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    50. Importance of Radiation Oncologist Experience Among Patients With Head-and-Neck Cancer Treated With Intensity-Modulated Radiation Therapy. J Clin Oncol. 2016 Mar 01; 34(7):684-90. Boero IJ, Paravati AJ, Xu B, Cohen EE, Mell LK, Le QT, Murphy JD. PMID: 26729432.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    51. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12(1):1-222. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algül H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Bánhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolomé A, Bassham DC, Bassi MT, Bast RC, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Becker C, Beckham JD, Bédard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, Bénard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Böckler S, Boes M, Boesze-Battaglia K, Boise LH, Bolino A, Boman A, Bonaldo P, Bordi M, Bosch J, Botana LM, Botti J, Bou G, Bouché M, Bouchecareilh M, Boucher MJ, Boulton ME, Bouret SG, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady N, Braga VM, Brancolini C, Braus GH, Bravo-San Pedro JM, Brennan LA, Bresnick EH, Brest P, Bridges D, Bringer MA, Brini M, Brito GC, Brodin B, Brookes PS, Brown EJ, Brown K, Broxmeyer HE, Bruhat A, Brum PC, Brumell JH, Brunetti-Pierri N, Bryson-Richardson RJ, Buch S, Buchan AM, Budak H, Bulavin DV, Bultman SJ, Bultynck G, Bumbasirevic V, Burelle Y, Burke RE, Burmeister M, Bütikofer P, Caberlotto L, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calatayud S, Camougrand N, Campanella M, Campbell GR, Campbell M, Campello S, Candau R, Caniggia I, Cantoni L, Cao L, Caplan AB, Caraglia M, Cardinali C, Cardoso SM, Carew JS, Carleton LA, Carlin CR, Carloni S, Carlsson SR, Carmona-Gutierrez D, Carneiro LA, Carnevali O, Carra S, Carrier A, Carroll B, Casas C, Casas J, Cassinelli G, Castets P, Castro-Obregon S, Cavallini G, Ceccherini I, Cecconi F, Cederbaum AI, Ceña V, Cenci S, Cerella C, Cervia D, Cetrullo S, Chaachouay H, Chae HJ, Chagin AS, Chai CY, Chakrabarti G, Chamilos G, Chan EY, Chan MT, Chandra D, Chandra P, Chang CP, Chang RC, Chang TY, Chatham JC, Chatterjee S, Chauhan S, Che Y, Cheetham ME, Cheluvappa R, Chen CJ, Chen G, Chen GC, Chen G, Chen H, Chen JW, Chen JK, Chen M, Chen M, Chen P, Chen Q, Chen Q, Chen SD, Chen S, Chen SS, Chen W, Chen WJ, Chen WQ, Chen W, Chen X, Chen YH, Chen YG, Chen Y, Chen Y, Chen Y, Chen YJ, Chen YQ, Chen Y, Chen Z, Chen Z, Cheng A, Cheng CH, Cheng H, Cheong H, Cherry S, Chesney J, Cheung CH, Chevet E, Chi HC, Chi SG, Chiacchiera F, Chiang HL, Chiarelli R, Chiariello M, Chieppa M, Chin LS, Chiong M, Chiu GN, Cho DH, Cho SG, Cho WC, Cho YY, Cho YS, Choi AM, Choi EJ, Choi EK, Choi J, Choi ME, Choi SI, Chou TF, Chouaib S, Choubey D, Choubey V, Chow KC, Chowdhury K, Chu CT, Chuang TH, Chun T, Chung H, Chung T, Chung YL, Chwae YJ, Cianfanelli V, et al. PMID: 26799652.
      View in: PubMed   Mentions: 1474     Fields:    Translation:HumansAnimals
    52. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23. Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE. PMID: 26598548.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    53. Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer. Patient Prefer Adherence. 2015; 9:1561-72. Fordham BA, Kerr C, de Freitas HM, Lloyd AJ, Johnston K, Pelletier CL, Tremblay G, Forsythe A, McIver B, Cohen EE. PMID: 26604709.
      View in: PubMed   Mentions:
    54. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma. Clin Cancer Res. 2015 Dec 15; 21(24):5420-6. Yeung KT, Cohen EE. PMID: 26487760.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    55. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2015 Oct 10; 33(29):3305-13. Sacco AG, Cohen EE. PMID: 26351341.
      View in: PubMed   Mentions: 71     Fields:    Translation:Humans
    56. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9. O'Donnell PH, Karovic S, Karrison TG, Janisch L, Levine MR, Harris PJ, Polite BN, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. PMID: 26199386.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    57. Integrated genomic analysis suggests MLL3 is a novel candidate susceptibility gene for familial nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2015 Aug; 24(8):1222-8. Sasaki MM, Skol AD, Bao R, Rhodes LV, Chambers R, Vokes EE, Cohen EE, Onel K. PMID: 26014803.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    58. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015 May; 16(5):583-94. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE. PMID: 25892145.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansCTClinical Trials
    59. Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab. Cancer Immunol Res. 2015 May; 3(5):567-74. Taylor RJ, Saloura V, Jain A, Goloubeva O, Wong S, Kronsberg S, Nagilla M, Silpino L, de Souza J, Seiwert T, Vokes E, Villaflor V, Cohen EE. PMID: 25769300.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCellsCTClinical Trials
    60. Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metalloproteinase activity in head and neck carcinoma. Oral Oncol. 2015 May; 51(5):470-5. Raju SC, Hauff SJ, Lemieux AJ, Orosco RK, Gross AM, Nguyen LT, Savariar E, Moss W, Whitney M, Cohen EE, Lippman SM, Tsien RY, Ideker T, Advani SJ, Nguyen QT. PMID: 25735654.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    61. Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). Oral Oncol. 2015 May; 51(5):399-408. Price KA, Cohen EE. PMID: 25725588.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    62. Reply to s. Chakraborty et al. J Clin Oncol. 2015 Mar 10; 33(8):968. Cohen EE, Kocherginsky M, Karrison T, Seiwert TY, Haraf DJ, Brockstein B, Vokes EE. PMID: 25667282.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    63. Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. Cancer Lett. 2015 Apr 10; 359(2):269-74. Schechter RB, Nagilla M, Joseph L, Reddy P, Khattri A, Watson S, Locati LD, Licitra L, Greco A, Pelosi G, Carcangiu ML, Lingen MW, Seiwert TY, Cohen EE. PMID: 25641339.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    64. Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Target Oncol. 2015 Dec; 10(4):501-8. Young NR, Soneru C, Liu J, Grushko TA, Hardeman A, Olopade OI, Baum A, Solca F, Cohen EE. PMID: 25559287.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    65. Towards a personalized treatment of head and neck cancer. Am Soc Clin Oncol Educ Book. 2015; 28-32. Gross AM, Cohen EE. PMID: 25993138.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    66. Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer. Cancer. 2015 Apr 15; 121(8):1303-11. Xu B, Boero IJ, Hwang L, Le QT, Moiseenko V, Sanghvi PR, Cohen EE, Mell LK, Murphy JD. PMID: 25537836.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    67. Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2015 Apr; 51(4):291-8. Simpson DR, Mell LK, Cohen EE. PMID: 25532816.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    68. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015 Feb 15; 21(4):870-81. Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, Brägelmann J, DeBoer R, El-Dinali M, Aktolga S, Lei Z, Tan P, Rozen SG, Salgia R, Weichselbaum RR, Lingen MW, Story MD, Ang KK, Cohen EE, White KP, Vokes EE, Seiwert TY. PMID: 25492084.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCells
    69. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials. 2014 Nov 29; 15:469. Burtness B, Bourhis JP, Vermorken JB, Harrington KJ, Cohen EE. PMID: 25432788.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    70. Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205. Das LC, Karrison TG, Witt ME, Muller C, Stenson K, Blair EA, Cohen EEW, Seiwert TY, Haraf DJ, Vokes EE. PMID: 25361984.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    71. Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1279-89. Tortorici MA, Cohen EE, Pithavala YK, Garrett M, Ruiz-Garcia A, Kim S, Fruehauf JP. PMID: 25336084.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    72. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014 12; 74(6):1261-70. Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P. PMID: 25315258.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    73. Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncol. 2015 Jan; 51(1):53-8. Khattri A, Zuo Z, Brägelmann J, Keck MK, El Dinali M, Brown CD, Stricker T, Munagala A, Cohen EE, Lingen MW, White KP, Vokes EE, Seiwert TY. PMID: 25255959.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    74. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet. 2014 Sep; 46(9):939-43. Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, Hofree M, Choueiri M, Coffey CS, Lippman SM, Hayes DN, Cohen EE, Grandis JR, Nguyen QT, Ideker T. PMID: 25086664.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    75. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb 01; 21(3):632-41. Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, Brown C, Pugh TJ, Stojanov P, Cho J, Lawrence MS, Getz G, Brägelmann J, DeBoer R, Weichselbaum RR, Langerman A, Portugal L, Blair E, Stenson K, Lingen MW, Cohen EE, Vokes EE, White KP, Hammerman PS. PMID: 25056374.
      View in: PubMed   Mentions: 158     Fields:    Translation:HumansCells
    76. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43. Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE. PMID: 25049329.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCTClinical Trials
    77. DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer. PLoS One. 2014; 9(7):e102112. Seiwert TY, Wang X, Heitmann J, Villegas-Bergazzi V, Sprott K, Finn S, O'Regan E, Farrow AD, Weichselbaum RR, Lingen MW, Cohen EE, Stenson K, Weaver DT, Vokes EE. PMID: 25019640.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    78. Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. BMC Cancer. 2014 Jun 28; 14:473. Machiels JP, Licitra LF, Haddad RI, Tahara M, Cohen EE. PMID: 24973959.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    79. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 2014 Sep; 25(9):1813-1820. Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, Degardin M, Zhang W, Blackman A, Ehrnrooth E, Cohen EEW. PMID: 24928832.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    80. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer. 2014 09 01; 120(17):2694-703. Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK, Bycott P, Cohen EE. PMID: 24844950.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    81. Eruptive cutaneous squamous cell carcinoma and psoriasis: response to cetuximab. Clin Exp Dermatol. 2014 Jul; 39(5):604-7. Kamaria M, Shea CR, Chin RK, Cohen EE, Maggiore R, Bolotin D. PMID: 24758726.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    82. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2014 Jun; 73(6):1227-39. Saloura V, Cohen EE, Licitra L, Billan S, Dinis J, Lisby S, Gauler TC. PMID: 24714973.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    83. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35. Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. PMID: 24637941.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    84. p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors. PLoS One. 2014; 9(3):e90171. Kuo WL, Sharifi MN, Lingen MW, Ahmed O, Liu J, Nagilla M, Macleod KF, Cohen EE. PMID: 24599075.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    85. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours. Eur J Cancer. 2014 Mar; 50(5):876-84. Hollebecque A, Houédé N, Cohen EE, Massard C, Italiano A, Westwood P, Bumgardner W, Miller J, Brail LH, Benhadji KA, Soria JC. PMID: 24456794.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    86. Race and competing mortality in advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):40-4. Zakeri K, MacEwan I, Vazirnia A, Cohen EE, Spiotto MT, Haraf DJ, Vokes EE, Weichselbaum RR, Mell LK. PMID: 24134948.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    87. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29):3639-46. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. PMID: 24002501.
      View in: PubMed   Mentions: 229     Fields:    Translation:HumansCTClinical Trials
    88. Study of functional infrared imaging for early detection of mucositis in locally advanced head and neck cancer treated with chemoradiotherapy. Oral Oncol. 2013 Oct; 49(10):1025-31. Cohen EE, Ahmed O, Kocherginsky M, Shustakova G, Kistner-Griffin E, Salama JK, Yefremenko V, Novosad V. PMID: 23988569.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    89. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70. Bhatta SS, Wroblewski KE, Agarwal KL, Sit L, Cohen EE, Seiwert TY, Karrison T, Bakris GL, Ratain MJ, Vokes EE, Maitland ML. PMID: 23900000.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    90. A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia. Oral Oncol. 2013 Sep; 49(9):970-976. Wong SJ, Campbell B, Massey B, Lynch DP, Cohen EEW, Blair E, Selle R, Shklovskaya J, Jovanovic BD, Skripkauskas S, Dew A, Kulesza P, Parimi V, Bergan RC, Szabo E. PMID: 23845699.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    91. Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. J Geriatr Oncol. 2013 Oct; 4(4):327-33. Maggiore RJ, Curran EK, Witt ME, Haraf DJ, Vokes EE, Cohen EE. PMID: 24472475.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    92. Pharmacoeconomic issues in head and neck oncology. Curr Opin Oncol. 2013 May; 25(3):213-7. de Souza JA, de Lima Lopes G, Cohen EE. PMID: 23508082.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    93. Modifiable risk behaviors in patients with head and neck cancer. Cancer. 2013 Jul 01; 119(13):2419-26. Sivasithamparam J, Visk CA, Cohen EE, King AC. PMID: 23575663.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    94. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67. Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EE. PMID: 23553850.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    95. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013 Jun; 13(6):729-36. Yang JC, Reguart N, Barinoff J, Köhler J, Uttenreuther-Fischer M, Stammberger U, O'Brien D, Wolf J, Cohen EE. PMID: 23506556.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    96. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncol. 2013 Jun; 49(6):525-33. Brägelmann J, Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, Kocherginsky M, Alexander K, Salgia R, Lingen MW, Vokes EE, White KP, Cohen EE, Seiwert TY. PMID: 23490885.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    97. Multidisciplinary care of the patient with head and neck cancer. Surg Oncol Clin N Am. 2013 Apr; 22(2):179-215. Saloura V, Langerman A, Rudra S, Chin R, Cohen EE. PMID: 23453331.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    98. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol. 2013 Jun; 7(3):359-68. Young NR, Liu J, Pierce C, Wei TF, Grushko T, Olopade OI, Liu W, Shen C, Seiwert TY, Cohen EE. PMID: 23200321.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    99. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76. Seiwert TY, Darga T, Haraf D, Blair EA, Stenson K, Cohen EE, Salama JK, Villaflor V, Witt ME, Lingen MW, Weichselbaum RR, Vokes EE. PMID: 23104721.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    100. Cabozantinib for the treatment of advanced medullary thyroid cancer. Adv Ther. 2012 Nov; 29(11):925-34. Nagilla M, Brown RL, Cohen EE. PMID: 23104465.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    101. Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. Oral Oncol. 2013 Mar; 49(3):277-82. Golden DW, Rudra S, Witt ME, Nwizu T, Cohen EE, Blair E, Stenson KM, Vokes EE, Haraf DJ. PMID: 23102863.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    102. The future of induction chemotherapy for head and neck squamous cell carcinoma. Oral Oncol. 2012 Nov; 48(11):1065-7. Haigentz M, Cohen EE, Wolf GT, Strojan P, Eisbruch A, Ferlito A. PMID: 22981388.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    103. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 01; 18(17):4785-93. Cohen EE, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ. PMID: 22872575.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCTClinical Trials
    104. The role of chemotherapy in locally advanced head and neck squamous cell carcinoma. Semin Radiat Oncol. 2012 Jul; 22(3):198-206. Nwizu T, Ghi MG, Cohen EE, Paccagnella A. PMID: 22687944.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    105. Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncol. 2012 Oct; 48(10):1025-1030. Mouw KW, Solanki AA, Stenson KM, Witt ME, Blair EA, Cohen EEW, Vokes EE, List M, Haraf DJ, Salama JK. PMID: 22621836.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    106. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012 Sep; 48(9):887-92. Perez CA, Song H, Raez LE, Agulnik M, Grushko TA, Dekker A, Stenson K, Blair EA, Olopade OI, Seiwert TY, Vokes EE, Cohen EE. PMID: 22513208.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    107. New approaches to thyroid cancer. Clin Adv Hematol Oncol. 2012 Apr; 10(4):255-6. Cohen EE. PMID: 22706487.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    108. Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy. Oral Oncol. 2012 Aug; 48(8):723-9. Urba S, Gatz J, Shen W, Hossain A, Winfree K, Koustenis A, Peterson P, Cohen EE. PMID: 22414289.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    109. Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol. 2012 Mar; 13(1):35-46. Price KA, Cohen EE. PMID: 22252884.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCells
    110. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15; 18(8):2336-43. de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, Wong SJ, Kozloff MF, Nattam S, Lingen MW, Kunnavakkam R, Stenson KM, Blair EA, Bozeman J, Dancey JE, Vokes EE, Cohen EE. PMID: 22371453.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    111. Single sample expression-anchored mechanisms predict survival in head and neck cancer. PLoS Comput Biol. 2012 Jan; 8(1):e1002350. Yang X, Regan K, Huang Y, Zhang Q, Li J, Seiwert TY, Cohen EE, Xing HR, Lussier YA. PMID: 22291585.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    112. Novel targeted therapies in head and neck cancer. Expert Opin Investig Drugs. 2012 Mar; 21(3):281-95. Ferreira MB, Lima JP, Cohen EE. PMID: 22239178.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    113. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012 Apr 01; 18(7):2056-65. Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen EE. PMID: 22241789.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    114. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8. Cohen EE, Subramanian J, Gao F, Szeto L, Kozloff M, Faoro L, Karrison T, Salgia R, Govindan R, Vokes EE. PMID: 22100149.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    115. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR. PMID: 22020702.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCTClinical Trials
    116. The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1629-32. Ramírez J, Wu K, Janisch L, Karrison T, House LK, Innocenti F, Cohen EE, Ratain MJ. PMID: 21861128.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    117. Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol. 2011 Jul 26; 3:31. Pederson AW, Salama JK, Haraf DJ, Witt ME, Stenson KM, Portugal L, Seiwert T, Villaflor VM, Cohen EE, Vokes EE, Blair EA. PMID: 21791072.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    118. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011 Oct 15; 117(20):4671-8. Choe KS, Haraf DJ, Solanki A, Cohen EE, Seiwert TY, Stenson KM, Blair EA, Portugal L, Villaflor VM, Witt ME, Vokes EE, Salama JK. PMID: 21671479.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    119. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. PMID: 21606412.
      View in: PubMed   Mentions: 162     Fields:    Translation:HumansCTClinical Trials
    120. Novel molecular targeted therapies for refractory thyroid cancer. Head Neck. 2012 May; 34(5):736-45. Perez CA, Santos ES, Arango BA, Raez LE, Cohen EE. PMID: 21544895.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    121. Role of molecular markers in the management of head and neck cancers. Curr Opin Oncol. 2011 May; 23(3):259-64. Ferreira MB, De Souza JA, Cohen EE. PMID: 21358329.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    122. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011 Jun 01; 17(11):3841-9. Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Bair AH, Ricart AD, Olszanski AJ, Letrent KJ, Kim S, Rixe O. PMID: 21531811.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    123. Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res. 2011 Apr 01; 17(7):1956-63. Gangadhar TC, Cohen EE, Wu K, Janisch L, Geary D, Kocherginsky M, House LK, Ramirez J, Undevia SD, Maitland ML, Fleming GF, Ratain MJ. PMID: 21447721.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    124. Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin. Head Neck. 2011 Dec; 33(12):1774-82. Liu J, Kuo WL, Seiwert TY, Lingen M, Ciaccio MF, Jones RB, Rosner MR, Cohen EE. PMID: 21438065.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    125. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9. Cohen EE, Sharma MR, Janisch L, Llobrera M, House L, Wu K, Ramirez J, Fleming GF, Stadler WM, Ratain MJ. PMID: 21439817.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    126. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Nov; 22(11):2501-2507. Villaflor VM, Haraf D, Salama JK, Kocherginsky M, Langerman A, Gomez-Abuin G, Beniwal P, Blair EA, Stenson KM, Portugal L, Seiwert T, Williams RD, Dekker AJ, Witt ME, Vokes EE, Cohen EEW. PMID: 21385883.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    127. Airway management before chemoradiation for advanced head and neck cancer. Head Neck. 2012 Feb; 34(2):254-9. Langerman A, Patel RM, Cohen EE, Blair EA, Stenson KM. PMID: 21384461.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    128. The next phase of chemoprevention research. Cancer Prev Res (Phila). 2011 Mar; 4(3):293-5. Cohen EE, Schilsky RL. PMID: 21372026.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    129. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol. 2011 Oct; 22(10):2304-9. Salama JK, Haraf DJ, Stenson KM, Blair EA, Witt ME, Williams R, Kunnavakkam R, Cohen EE, Seiwert T, Vokes EE. PMID: 21330337.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    130. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res. 2011 May; 157(5):265-72. Ziliak D, O'Donnell PH, Im HK, Gamazon ER, Chen P, Delaney S, Shukla S, Das S, Cox NJ, Vokes EE, Cohen EE, Dolan ME, Huang RS. PMID: 21497773.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    131. Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2010 Dec; 136(12):1226-34. Mouw KW, Haraf DJ, Stenson KM, Cohen EE, Xi X, Witt ME, List M, Blair EA, Vokes EE, Salama JK. PMID: 21173372.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    132. Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. Radiother Oncol. 2010 Nov; 97(2):318-21. Choe KS, Salama JK, Stenson KM, Blair EA, Witt ME, Cohen EE, Haraf DJ, Vokes EE. PMID: 20934766.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    133. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. . 2010 Oct; 9(10):2814-24. Kuo WL, Liu J, Mauceri H, Vokes EE, Weichselbaum R, Rosner MR, Cohen EE. PMID: 20876745.
      View in: PubMed   Mentions:
    134. [18F]Fluorodeoxyglucose positron emission tomography in the initial staging of squamous cell carcinoma of the head and neck: promise, evidence, and reality. J Clin Oncol. 2010 Oct 01; 28(28):e516; author reply e517. de Souza JA, Cohen EE. PMID: 20606097.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    135. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43. Cohen EE, Haraf DJ, Kunnavakkam R, Stenson KM, Blair EA, Brockstein B, Lester EP, Salama JK, Dekker A, Williams R, Witt ME, Grushko TA, Dignam JJ, Lingen MW, Olopade OI, Vokes EE. PMID: 20498391.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    136. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res. 2010 May 01; 16(9):2489-95. Chen LF, Cohen EE, Grandis JR. PMID: 20406834.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    137. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 2010 Mar 15; 70(6):2158-64. Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, Sadow PM, Sooriyakumar G, Brannigan BW, Ulman MJ, Perera RM, Wang R, Tam A, Ma XJ, Erlander M, Sgroi DC, Rocco JW, Lingen MW, Cohen EE, Louis DN, Settleman J, Haber DA. PMID: 20215515.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    138. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev. 2010 Feb; 19(2):358-65. Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE. PMID: 20086114.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    139. Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope. 2010 Jan; 120(1):93-9. Stenson KM, Kunnavakkam R, Cohen EE, Portugal LD, Blair E, Haraf DJ, Salama J, Vokes EE. PMID: 19856305.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    140. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010 Jan 01; 28(1):15-20. Mell LK, Dignam JJ, Salama JK, Cohen EE, Polite BN, Dandekar V, Bhate AD, Witt ME, Haraf DJ, Mittal BB, Vokes EE, Weichselbaum RR. PMID: 19933920.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    141. Personalizing cancer care: updates on head and neck cancer. Expert Rev Anticancer Ther. 2009 Sep; 9(9):1219-22. de Souza JA, Cohen EE. PMID: 19761425.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    142. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010 Oct; 28(5):677-83. Choong NW, Kozloff M, Taber D, Hu HS, Wade J, Ivy P, Karrison TG, Dekker A, Vokes EE, Cohen EE. PMID: 19649772.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    143. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21. Cohen EE, Baru J, Huo D, Haraf DJ, Crowley M, Witt ME, Blair EA, Weichselbaum RR, Rosen F, Vokes EE, Stenson K. PMID: 19340870.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    144. Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck. 2009 Aug; 31(8):1006-12. Vidal L, Tsao MS, Pond GR, Cohen EE, Cohen RB, Chen EX, Agulnik M, Hotte S, Winquist E, Laurie S, Hayes DN, Ho J, Dancey J, Siu LL. PMID: 19309723.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    145. Mechanisms of resistance to EGFR inhibitors in head and neck cancer. Head Neck. 2009 Aug; 31(8):1086-94. Cooper JB, Cohen EE. PMID: 19378324.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    146. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2009 Oct; 45(10):e155-60. Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE. PMID: 19586795.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    147. Surrogate endpoints in head and neck cancer. Lancet Oncol. 2009 Apr; 10(4):309-10. Chen L, Cohen EE. PMID: 19341966.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    148. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. PMID: 19318576.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansAnimalsCells
    149. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009 Apr 10; 27(11):1864-71. Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE. PMID: 19289630.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCTClinical Trials
    150. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE. PMID: 19201650.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCTClinical Trials
    151. Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents. J Biopharm Stat. 2009; 19(3):524-9. Kocherginsky M, Cohen EE, Karrison T. PMID: 19384693.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    152. A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res. 2009 Jan 01; 69(1):65-74. Cohen EE, Zhu H, Lingen MW, Martin LE, Kuo WL, Choi EA, Kocherginsky M, Parker JS, Chung CH, Rosner MR. PMID: 19117988.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    153. Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008 Oct; 134(10):1060-5. Salama JK, Stenson KM, List MA, Mell LK, Maccracken E, Cohen EE, Blair E, Vokes EE, Haraf DJ. PMID: 18936351.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    154. Free-flap reconstruction in the doubly irradiated patient population. Plast Reconstr Surg. 2008 Jul; 122(1):125-32. Cohn AB, Lang PO, Agarwal JP, Peng SL, Alizadeh K, Stenson KM, Haraf DJ, Cohen EE, Vokes EE, Gottlieb LJ. PMID: 18594395.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    155. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10; 26(29):4708-13. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. PMID: 18541897.
      View in: PubMed   Mentions: 197     Fields:    Translation:HumansCTClinical Trials
    156. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol. 2008 Oct; 19(10):1787-94. Salama JK, Stenson KM, Kistner EO, Mittal BB, Argiris A, Witt ME, Rosen F, Brockstein BE, Cohen EE, Haraf DJ, Vokes EE. PMID: 18539617.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    157. Targeting angiogenesis in head and neck cancer. Semin Oncol. 2008 Jun; 35(3):274-85. Seiwert TY, Cohen EE. PMID: 18544442.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    158. Introduction: head and neck cancer. Semin Oncol. 2008 Jun; 35(3):196-7. Vokes EE, Cohen EE, Grandis JR. PMID: 18544434.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    159. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun; 3(6):631-6. Mauer AM, Cohen EE, Ma PC, Kozloff MF, Schwartzberg L, Coates AI, Qian J, Hagey AE, Gordon GB. PMID: 18520803.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    160. Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann Oncol. 2008 Sep; 19(9):1650-4. Knab BR, Salama JK, Solanki A, Stenson KM, Cohen EE, Witt ME, Haraf DJ, Vokes EE. PMID: 18467314.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    161. Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clin Cancer Res. 2008 Apr 15; 14(8):2253-62. Dougherty U, Sehdev A, Cerda S, Mustafi R, Little N, Yuan W, Jagadeeswaran S, Chumsangsri A, Delgado J, Tretiakova M, Joseph L, Hart J, Cohen EE, Aluri L, Fichera A, Bissonnette M. PMID: 18413814.
      View in: PubMed   Mentions: 29     Fields:    Translation:Animals
    162. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41. Seiwert TY, Haraf DJ, Cohen EE, Stenson K, Witt ME, Dekker A, Kocherginsky M, Weichselbaum RR, Chen HX, Vokes EE. PMID: 18375903.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    163. mTOR: the mammalian target of replication. J Clin Oncol. 2008 Jan 20; 26(3):348-9. Cohen EE. PMID: 18202406.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    164. Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. Curr Cancer Drug Targets. 2007 Nov; 7(7):666-73. Ahmed SM, Cohen EE. PMID: 18045071.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    165. A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. Qual Life Res. 2007 Dec; 16(10):1615-26. Yount S, List M, Du H, Yost K, Bode R, Brockstein B, Argiris A, Vokes E, Cohen EE, Campbell B, Valenzuela V, George J, Egan R, Chen J, Meddis D, Cella D. PMID: 17922221.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    166. A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer. Cancer Invest. 2007 Sep; 25(6):435-44. Seiwert TY, Cohen EE, Haraf DJ, Stenson K, Blair EA, Mauer A, Dekker A, Vokes EE. PMID: 17882655.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    167. A disturbance in the force--mitochondrial mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 1):4317-9. Cohen EE. PMID: 17671110.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    168. The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol. 2007 Aug 10; 25(23):3397-8. Ratain MJ, Cohen EE. PMID: 17635950.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    169. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 01; 67(3):678-84. Cohen EE, Rosine D, Haraf DJ, Loh E, Shen L, Lusinchi A, Vokes EE, Bourhis J. PMID: 17293229.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    170. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20; 24(21):3438-44. Cohen EE, Haraf DJ, List MA, Kocherginsky M, Mittal BB, Rosen F, Brockstein B, Williams R, Witt ME, Stenson KM, Kies MS, Vokes EE. PMID: 16849759.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    171. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res. 2006 Jun 15; 66(12):6296-303. Cohen EE, Lingen MW, Zhu B, Zhu H, Straza MW, Pierce C, Martin LE, Rosner MR. PMID: 16778206.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    172. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006 Jun 10; 24(17):2659-65. Cohen EE. PMID: 16763280.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    173. Iodine-refractory thyroid carcinoma. Rev Recent Clin Trials. 2006 May; 1(2):133-41. Ganti AK, Cohen EE. PMID: 18473964.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    174. Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006 Jan; 116(1):33-6. Stenson KM, Huo D, Blair E, Cohen EE, Argiris A, Haraf DJ, Vokes EE. PMID: 16481805.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    175. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005 Dec 01; 11(23):8418-24. Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE. PMID: 16322304.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    176. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8. Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW. PMID: 16299242.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    177. Epidermal growth factor receptor directed therapy in head and neck cancer. Crit Rev Oncol Hematol. 2006 Jan; 57(1):25-43. Choong NW, Cohen EE. PMID: 16207530.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    178. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer. 2005 Apr 25; 92(8):1341-8. Seiwert TY, Cohen EE. PMID: 15846296.
      View in: PubMed   Mentions: 71     Fields:    Translation:Humans
    179. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004 Dec; 25(6):1677-83. Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE, Weichselbaum RR. PMID: 15547705.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    180. Novel therapeutic targets in squamous cell carcinoma of the head and neck. Semin Oncol. 2004 Dec; 31(6):755-68. Cohen EE. PMID: 15599853.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    181. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol. 2004 May 01; 22(9):1743-52. Cohen EE, Lingen MW, Vokes EE. PMID: 15117998.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    182. Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Hematol Oncol Clin North Am. 2004 Feb; 18(1):81-90. Cohen EE, Vokes EE. PMID: 15005282.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    183. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol. 2003 Dec 15; 21(24):4546-52. Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S, Recant W, El-Naggar AK, Stenson K, Lippman SM, Hong WK, Vokes EE. PMID: 14597742.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCellsCTClinical Trials
    184. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003 May 15; 21(10):1980-7. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. PMID: 12743152.
      View in: PubMed   Mentions: 131     Fields:    Translation:HumansCTClinical Trials
    185. Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. Lung Cancer. 2002 Oct; 38(1):65-71. Hoffman PC, Cohen EE, Masters GA, Haraf DJ, Mauer AM, Rudin CM, Krauss SA, Huo D, Vokes EE. PMID: 12367795.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    186. Searching for a standard. J Clin Oncol. 2002 Jan 15; 20(2):359-61. Cohen EE, Vokes EE. PMID: 11786560.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    187. Esophageal cancer therapy: a decade of inertia. Cancer J. 2001 Sep-Oct; 7(5):369-71. Cohen EE, Vokes EE. PMID: 11693893.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    188. Locally advanced non-small cell lung cancer. Curr Treat Options Oncol. 2001 Feb; 2(1):27-42. Cohen EE, Vokes EE. PMID: 12057138.
      View in: PubMed   Mentions:    Fields:    Translation:Humans